---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039049"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:03:30.170015+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q2 core lung diagnostics revenue up 58% YoY to $11.4M; raises $27.5M

## Summary
- Core lung diagnostic revenue $11.4M (+58% YoY, +33% QoQ); gross margin 73% vs 64% in Q2 2022.
- Net loss $13.4M improved 16% YoY; cash burn reduced 56% QoQ to $7.9M.
- Raised $27.5M in private placement post-quarter from largest shareholders, board, and management.
- Reaffirmed FY2023 total revenue guidance of $52-55M.
- Achieved primary endpoint of ORACLE study: 74% reduction in unnecessary procedures using Nodify XL2.

## SEC filing metadata
- accession: 0000950170-23-039049
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/0000950170-23-039049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/bdsx-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039049
- JSON: https://secwatch.observer/filing/0000950170-23-039049.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039049.txt

## Key facts
- Earnings Releases
  BIODESIX INC updated its second quarter ended June 30, 2023 guidance (reaffirmed).
  - Period: second quarter ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On August 7, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/0000950170-23-039049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.